114
Participants
Start Date
October 18, 2021
Primary Completion Date
October 31, 2022
Study Completion Date
December 31, 2022
TQC3721 suspension for inhalation
Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0 mg/24.0 mg single dose of TQC3721 suspension for inhalation.
TQC3721 suspension placebo for inhalation
Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation .
RECRUITING
West China Hospital of Sichuan University, Chengdu
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY